Long‐Term Safety of Extremely Low‐Dose Amiodarone at 50 mg Daily in Patients With Persistent Atrial Fibrillation

Documenti analoghi

• Reply to “Challenges to the Long‐Term Safety Claims of Extremely Low‐Dose Amiodarone: Pulmonary, Thyroid, Hepatic, and Statistical Concerns”
  di: Kentaro Yoshida
  Pubblicazione: (2025)
• Electrophysiological Characteristics of Atrial Fibrillation Trigger Sites During Ongoing Atrial Fibrillation Using Ultra‐High‐Resolution Mapping
  di: Kohki Nakamura, et al.
  Pubblicazione: (2026)
• Successful debulking of vegetation extending into the right ventricle using a steerable sheath and leadless retrieval system
  di: Yoshiki Aono, et al.
  Pubblicazione: (2025)
• Suspected Cardioembolic Stroke Linked to Left Atrial Stunning After Pulsed Field Ablation for Atrial Fibrillation
  di: Akinori Matsushima, et al.
  Pubblicazione: (2026)
• Reduced Kidney Function and Left Atrial Dilatation as Predictors of Incident Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
  di: Yuriko Tsumaya, et al.
  Pubblicazione: (2025)